Imbalanced Bispecific Antibody Technology Platform "KIH” + commonlight chain format: Similar to Emicizumab "Imbalanced” Dual antigen binding: Best fit for each unique MOA CAAD: Designed common LC + designed ideal biochemical and biophysical features
Development of a novel "imbalanced" CSA bispecific antibody by computational design
Case StudyDevelopment of Multi-Specific Antibodies by Computational Design
Case StudyAb Studio's Internalizing Antibody Case Study: Antibody Against Cancer Antigen-X
Case Study